[go: up one dir, main page]

WO2014090832A1 - Tannin derivative and pharmaceutical compositions comprising said tannin derivative - Google Patents

Tannin derivative and pharmaceutical compositions comprising said tannin derivative Download PDF

Info

Publication number
WO2014090832A1
WO2014090832A1 PCT/EP2013/076140 EP2013076140W WO2014090832A1 WO 2014090832 A1 WO2014090832 A1 WO 2014090832A1 EP 2013076140 W EP2013076140 W EP 2013076140W WO 2014090832 A1 WO2014090832 A1 WO 2014090832A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
tannin
pharmaceutically active
antibiotics
tannin derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/076140
Other languages
French (fr)
Inventor
Markus Bogner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of WO2014090832A1 publication Critical patent/WO2014090832A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H6/00—Macromolecular compounds derived from lignin, e.g. tannins, humic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Tannin derivative and pharmaceutical compositions comprising said tannin derivative
  • the present invention relates to a tannin derivative, in particular tannin derivative having antibiotic activity and pharmaceutical compositions comprising said tannin derivative.
  • Tannins are distributed in species throughout the plant kingdom. They are commonly found in both gymnosperms as well as angiosperms.
  • a tannin also known as vegetable tannin, natural organic tannins or sometimes tannoid, i.e. a type of biomolecule, as opposed to modern synthetic tannin
  • the term tannin in the context of the present invention comprises any large polyphenolic compound containing sufficient hydroxyls and other suitable groups (such as carboxyls) to form strong complexes with proteins and other macromolecules.
  • tannin compounds play a key role in protection of plants from predation by fungi, insects and other abiotic agents. Tannin compounds are also supposed to play a key role as pesticides, and in plant growth regulation.
  • the astringency of tannins is what causes the dry and puckery feeling in the mouth following the consumption of unripened fruit or red wine.
  • the destruction or modification of tannins with time plays an important role in the ripening of fruit and the aging of wine.
  • Tannins have molecular weights ranging from 500 to over 3,000 (gallic acid esters) and up to 20,000 (proanthocyanidins). Tannins are incompatible with alkalis, gelatin, heavy metals, iron, limewater, metallic salts, strong oxidizing agents and zinc sulfate, since they form complexes and precipitate in aqueous solution.
  • tannins isolated from the stem bark also have antiinflammatory and antiulcer activity in rodents, showing a strong antioxidant property with possible therapeutic applications.
  • Tannin derivative galloyi glucose is a chemical compound formed from gallic acid and ⁇ - D-glucose. It can be found in oaks species like the North American white oak (Quercus alba) and European red oak (Quercus robur) and may be synthesized artificially.
  • Galloyi glucose is formed by a gallate 1 -beta-glucosyltransferase (UDP-glucose: gallate glucosyl transferase), an enzyme performing the esterification of two substrates, UDP- glucose and gallate to yield two products, UDP and 1 -galloyl-beta-D-glucose (glucogallin). This enzyme can be found i.a. in oak leaves preparations.
  • Galloyi glucose carbon acid esters are substances having various properties that are about to exhibit pharmacological interest. Synthesis currently used provide for a derivatisation of gallic acid and coupling said gallic acid with glucose to yield galloyi glucose directly employable as antibiotic agent. The present invention however provides for the derivatisation of the entire molecule of galloyi glucose wherein the hydroxy groups of galloyi glucose become chemically modified.
  • US2008/0319185 discloses pentagalloyl glucose having hydroxy groups of gallic acid derivatized with benzen groups for mere stabilisation purposes.
  • Enzymatic esterification is the first step in the biosynthesis of galloyi glucose or gallotannins.
  • the molecule is then used by enzymes in the gallotannins synthetis pathway like beta-glucogallin O-galloyl transferase or beta-glucogallin-tetra-cis-galloyl glucose O-galloyl transferase.
  • Prior art anti-infective drug substances such as classical antibiotics have the disadvantage of decreasing efficiency due to increasing host resistance. Further these substances are found only effective against bacterial infections. Due to increasing occurrence of e.g. bacterial and fungal co-infections there is an increasing need of drug substances with increased efficiency against multiple microbial agents.
  • the present invention provides for tannin derivatives and a pharmaceutical compositions comprising said tannin derivative, effective for the treatment of multiple infections by different microbial agents. Furthermore, the tannin of the inventions provides for a vehicle to co-administer antimicrobial and other drug substances to a subject in need thereof. The invention thus provides for a molecule that may be applied in the synthesis of various drug substances useful for the synthesis of pharmaceutical compositions useful for treating co-infective diseases.
  • the invention provides for tannin derivative, in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin.
  • the main aspect of the present invention is, that the covalent coupling is formed as an ester or ether bond.
  • the acid residue thus provides at least one functional group for covalently coupling at least one pharmaceutically active ingredient.
  • a tannin derivative in which the at least one organic acid provides one or more aromatic groups.
  • a tannin derivative wherein the at least one tannin provides one or more substitutable hydroxyl groups.
  • the at least one tannin is selected from the group consisting of 1 -galloyl glucose, 2-galloyl glucose, tri-galloyl glucose, 4-galloyl glucose, penta-galloyl glucose or mixtures thereof.
  • the aromatic acid is selected from the group consisting of aromatic carboxylic acids such as amines, halogens and/or hydroxyl-containing aromatic carboxylic acids, benzoic acid or derivatives and/or mixtures thereof.
  • the tannin derivative provides a coupling of two or more identical or different aromatic acids, in particular wherein the aromatic acid is a pharmaceutically acceptable acid.
  • the at least one pharmaceutically active ingredient covalently coupled to the at least one functional group is selected from the group consisting of antibiotics, antifungals, cytostatics, antivirals, fungistatics, analgesics or combinations thereof.
  • the at least one pharmaceutically active ingredient is selected from the group consisting of HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV- effective antivirals or combinations thereof.
  • the tannin derivative of the invention thus provided antibiotic properties via the basic tannin structure or compound whereas this properties are completed by an antiviral property.
  • the preferred embodiment ma ythus be empoyed in the treatment of multiple infections with various pathogens in general requiring different active agents.
  • the invention composition thus enables treatment of different pathogens with a single multiactive compound.
  • the at least one pharmaceutically active ingredient is selected from the group consisting of ⁇ -lactame antibiotics, gram-positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics or combinations thereof.
  • the pharmaceutically active ingredient thus increases the efficiency of the underlying tannin derivative and provides for a broader range of antibiotic activity of the compound. Treatment of bacteria with increased resistance can thus be achieved with a single coumpound by different ways of pharmaceutical activity.
  • the at least one pharmaceutically active ingredient is selected from the group consisting of polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines echinocandins or combinatons thereof.
  • the tannin derivative thus combines antibiotic with antifungal activity.
  • the invention tannin derivative thus provide for a pharmaceutical compositions useful for treating co-infective diseases.
  • the at least one pharmaceutically active ingredient is selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p-aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid,
  • the tannin derivative in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin provides for the covalent coupling being formed as an ester or ether bond.
  • the acid residue provides at least one functional group for covalently coupling two or more pharmaceutically active ingredients.
  • the pharmaceutically active ingredients are preferably functionally and/or structurally identical or similar or functionally and/or structurally different.
  • the invention tannin derivative provides for integration of pharmaceutically active ingredients within molecule, whereas the pharmaceutically active ingredients and thus the molecule are adapted to treatment of various infections or infective indications occuring in an individual simultaneously or consecutively.
  • pharmaceutically active ingredients in particular functionally and/or structurally identical or functionally and/or structurally different pharmaceutically active ingredients are selected from the group consisting of antibiotics, preferably ⁇ -lactame antibiotics, gram- positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics, antifungals, preferably polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines or echinocandins, cytostatics, antivirals, preferably HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV-effective antivirals and fungistatics, analgesics. It is a particular advantage of the present invention that combinations of the aforesaid active ingredients may be combined in a single molecule. The effect of co-administration may thus be achieved by a single adaptive molecule combining several
  • the two or more pharmaceutically active ingredients are selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p-aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid, phenoxyacetic acid, phenylacrylic acid, serine, styrylacetic acid, (S)-2- ⁇ 4-[(2-4-di)
  • the tannin derivative is selected from a composition of formula (A),
  • R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same, similar or different pharmaceutically active ingredients.
  • the tannin derivative is selected from a composition of formula (B),
  • R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same, similar or different pharmaceutically active ingredients.
  • the tannin derivative is selected from a composition of formula (C),
  • R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same, similar or different pharmaceutically active ingredients.
  • the tannin derivative provides for a multitude of binding sites for pharmaceutically active ingredients.
  • a macromolecule may be synthesised comprising on or more pharmaceutically active ingredients.
  • the antibiotic activity of the underlying tannin may thus be combined with further pharmaceutical activity and allow for co-administration of pharmaceutically active ingredients thus increasing efficiency of treatment and reducing potential negative side effects.
  • Formula A shows galloyi glucose derivatised with p-aminobenzic acid
  • p-aminobenzic acid can be replaced by other pharmaceutically active molecules such as other carbon acids.
  • Coupling is effected by an ester group as shown in formula A.
  • ester group may be substituted by an ether group or any other chemical binding agent as shown e.g. in formula B.
  • An extension of the pharmaceutically active band width can be achieved by chemically binding further pharmaceutically active molecules (e.g. as defined above) to galloyi glucose.
  • long chained carbon acids could improve membrane permeability of the molecule.
  • coupling with e.g. vitamine molecules can be useful for infiltration of bacterial cells.
  • a particularly preferred active variant is the additional or sole coupling of beta-lactame molecule.
  • Formula C suggests how a terminal amino group of derivated galloyi glucose as shown in formula A can be coupled using Hantzsch reaction with a further pharmaceutically active group of molecules.
  • galloyi glucose As the basic molecule of galloyi glucose is able to form complexes of iron ions and to unspecifically denature proteins, the derivatisation of galloyi glucose as described above further provides additional modes of action against pathogens.
  • the present invention also provides for a pharmaceutical composition
  • a pharmaceutical composition comprising or consisting of at least one tannin derivative as defined above.
  • said pharmaceutical composition has a solid, orally administrable form, a liquid, orally administrable form, an injectably administrable form or in form of an ointment, an emulsion or a suspension.
  • the dosage form comprises a mixture of pharmaceutical composition and excipients and may be pressed or compacted from a powder into a solid dose or mixed to form a liquid orally administrable form, an injectably administrable form or an ointment, an emulsion or a suspension.
  • the excipients can include but are not limited to diluents, binders or granulating agents, flow aids and lubricants to ensure efficient tabletting; disintegrants to promote tablet break-up in the digestive tract; sweeteners or flavours to enhance taste; and pigments to make the tablets or other adminstrable forms visually attractive.
  • the pharmaceutical composition may be provided in a form administrable orally, sublingually, buccally, rectally or intravaginally. Further contemplated administrable forms are syrups, elixirs, suspensions, and emulsions.
  • Derivatives in particular of galloyi glucose and aromatic carbon acids as well as combinations of galloyi glucose and derivatives of the latter, preferably comprising amino, halogen or hydroxyl groups exhibit strong antimicrobial properties.
  • membrane permeability derivatives of the molecule preferably have a terminal carbon chain of suitable length.
  • the galloyi glucose derivative metabolized in a pathogen i.e. a bacterial cell, denatures proteins which, in the case of bacteria may avoid formation of resistance.
  • galloyi glucose derivative is able to form a complex with iron ions. This process will result in a reduction of iron availability within the microbial cell.
  • Tannin derivatives of the present invention thus provide antibacterial, antifungal, antiviral activity. Due to free hydroxyl groups anticancerogen activity is encompassed as well.
  • the present invention contemplates a method for producing a tannin derivatives, comprising the steps of i) providing a tannin, and ii) covalently coupling at least one aromatic acid or an acid derivative with at least one hydroxyl group of the tannin and iii) covalently coupling at least one pharmaceutically active ingredient as specified above with at least one functional group defined by the aromatic acid residue of the tannin derivative as specified above.
  • method ii) covalently coupling at least one aromatic acid or an acid derivative with at least one hydroxyl group of the tannin provides for an esterification or etherification of the aromatic acid or acid derivative in the presence of an alcohol and/or an acid.
  • a selective coupling with individual hydroxyl groups is provided.
  • selection is performed by binding of suitable protecting groups with the hydroxyl groups.
  • coupling may be directed to predetermined hydroxyl groups to further specify binding ability and selectivity of the invention pharmaceutical compositions. Protection groups suitable for use with the invention method are readily available for the skilled person.
  • coupling is effected in a Hantzsch reaction.
  • Hantzsch reaction is the preferred reaction for effecting coupling of the tannin derivative with pharmaceutically active ingredients
  • the invention also contemplated the use of other reactions, such as e.g. Biginelli reactions, mannich reactions and passerine reactions, without restricting the invention to the aforementioned reactions.
  • Persons skilled in the art are completely aware of possible modifications and further reactions that may be employed in the context of the invention method and are covered. These modifications are contemplated by the invention.
  • the invention also provides for a pharmaceutical or pharmaceutical composition comprising or consisting of the invention tannin derivative as specified above for use in medicine.
  • the pharmaceutical or pharmaceutical composition comprising or consisting of the invention tannin derivative as specified above is used as an antibiotic, antifungal, cytostatic, antiviral, analgesic and/or fungistatic or a combination of the aforesaid.
  • the invention pharmaceutical or pharmaceutical composition comprising or consisting of a tannin derivative as specified above is preferably employed for the therapy or prevention of infections, in particular bacterial diseases, virus diseases and/or mycoses.
  • the invention contemplates synthesis between galloyl glucose and substituted aromatic acids.
  • the isolated reaction product was tested with a test from milk industry, wherein Lactobacillus reduces the dyes methylene blue and brilliant black to a colorless form. If the reaction product is present in the medium no growth of Lactobacillus is reported. The dyes stay blue or black thus proving the reaction product of galloyl glucose and substituted aromatic acids to be effective as antimicrobial agent.
  • each hydroxyl group in the molecule of various tannins in particular galloyl glucose, can be used to make another substitution. Reaction may be directed by the use of specific protection groups.
  • the invention encompasses the case that the linking molecule, e. g. a pharmaceutically and physiologically acceptable substituted aromatic acids provides for a residual amino group, this amino group is used for a reaction, in particular Hantzsch reaction or any other suitable reaction, to build a pyrimidine, e.g. di-hydro-di-acetyl-pyrimidine which may be used as a precursor for a functionalized molecule.
  • 1 ,7g tannin and 5,1 g p-amino benzoic acid are placed with 50g ⁇ , ⁇ -dimethyl formamid in a 250ml 3-neck vessel. On top of the vessel was placed a water separation funnel with a cooler. Warming yielded a clear, brown solution. A solution consisting of 1 ,3g p- toluene sulfonic acid in 13g ⁇ , ⁇ -Dimethyl formamid and 86, 5g dry toluene was added. After 60 minutes of boiling 0,46g water was separated in the graduated water measuring funnel. The heating was stopped. To avoid oxidization of tannin synthesis steps were performed inert gas atmospheric conditions.
  • the reaction mixture was mixed with the same weight of n-hexane in a separating funnel. Following phase separation a heavy phase in the form of dark oil remained. The remaining n-hexane was removed by incubation in a 40°C bain-marie. Transition from free base into hydrochloride was performed using 1 -n hydrochloride acid under pH control. The weak acidic solution was mixed with 1 g of charcoal, filtered and incubated at 36°C in a crystallization glass for 24hrs. The resulting product was filtered and dried in a vacuum desiccator overnight. The synthesis yielded 1 ,49g of a brownish substance exhibiting perpendicularly, chromatic crystals in polarized light
  • Lactobacillus confirmed the antimicrobial activity of the yielded substance even if present in the growth medium at very low concentrations.
  • Tri-galloyl glucose (Corilagin) having the chemical formula C27H24O18 and a molecular weight of 636,47 is covalently coupled with physiologically acceptable p-Amino-benzoic acid by an ester bond thereby yielding p-Amino-benzoic acid-ester.
  • a pharmaceutically active ingredient Di-methyl-di-acetyl-pyrimidin- benzaldehyd is coupled to a functional group of p-Amino-benzoic acid-ester thus providing a functionalized molecule having on the one hand antibiotic characteristics provided by the tannin derivative on the other hand antianginal and antihypersensitive characteristics provided by the pharmaceutically active ingredient.
  • penta-galloyl glucose can be used, without restricting the invention to the aforesaid compounds.
  • reaction mixture Preparation of the reaction mixture (RGM) is effected by adding 30ml 1 -n HCI and repeated agitation in the presence of Ligroin for complete removal of toluol until ligroine phase weight shows no further increase.
  • the heavy phase containing the product as hydrochloride is stirred in the presence of 1 g active carbon, filtered.
  • the filtrate is set aside for cristallisation at +36°C. After approx. 24 hrs the cristals are aspired, dried and weighed.
  • the invention comprises the following items:
  • a tannin derivative in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin wherein the covalent coupling is formed as an ester or ether bond, and wherein the acid residue provides at least one functional group for covalently coupling at least one pharmaceutically active ingredient.
  • a tannin derivative wherein the at least one organic acid provides one or more aromatic groups.
  • a tannin derivative wherein the at least one tannin provides one or more substitutable hydroxyl groups.
  • a tannin derivative wherein the at least one tannin is selected from the group consisting of 1 -galloyl glucose, 2- galloyl glucose, tri-galloyl glucose, 4- galloyl glucose, penta- galloyl glucose or mixtures thereof.
  • a tannin derivative wherein the aromatic acid is selected from the group consisting of aromatic carboxylic acids such as amines, halogens and/or hydroxyl-containing aromatic carboxylic acids, benzoic acid or derivatives and/or mixtures thereof.
  • a tannin derivative wherein coupling of two or more identical or different aromatic acids is provided, preferably wherein the aromatic acid is a pharmaceutically acceptable acid.
  • a tannin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of antibiotics, antifungals, cytostatics, antivirals, fungistatics, analgesics or combinations thereof.
  • a tannin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV- effective antivirals or combinations thereof.
  • a tannin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of ⁇ -lactame antibiotics, gram-positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics or combinations thereof.
  • a tannin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines echinocandins or combinatons thereof.
  • At annin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p- aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid, phenoxyacetic acid, phenylacrylic acid, serine, styrylacetic acid, (S)-2- ⁇ 4-[(2-4-diaminopteridin-6-yl methyl) methylamino] benzoylamino ⁇ pentand
  • a tannin derivative in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin wherein the covalent coupling is formed as an ester or ether bond, and wherein the acid residue provides at least one functional group for covalently coupling two or more
  • pharmaceutically active ingredients in particular functionally identical or functionally different pharmaceutically active ingredients.
  • antibiotics preferably ⁇ -lactame antibiotics, gram-positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide
  • a tannin derivative wherein the tannin derivative is selected from a composition of formula (A),
  • R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same or different pharmaceutically active ingredients.
  • a tannin derivative wherein the tannin derivative is selected from a composition of formula (B),
  • R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same or different pharmaceutically active ingredients
  • a tannin derivative wherein the tannin derivative is selected from a composition of formula (C),
  • R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same or different pharmaceutically active ingredients.
  • a pharmaceutical composition comprising a tannin derivative as defined before in particular in a solid, orally administrable form, a liquid, orally administrable form, an injectably administrable form or in form of an ointment, an emulsion or a suspension.
  • a Method for producing a tannin derivatives as specified above comprising the steps of: i) providing a tannin, and ii) covalently coupling at least one aromatic acid or an acid derivative with at least one hydroxyl group of the tannin and iii) covalently coupling at least one pharmaceutically active ingredient with at least one functional group defined by the aromatic acid residue of the tannin derivative as specified above .
  • the aforementionned method wherein step ii) provides an esterification or etherification of the aromatic acid or acid derivative in the presence of an alcohol and/or an acid.
  • a pharmaceutical comprising or consisting of a tannin derivative as specified above or a pharmaceutical composition as defined above for use in medicine.
  • a pharmaceutical for use as an antibiotic, antifungal, cytostatic, antiviral and/or fungistatic is provided.
  • a pharmaceutical for the therapy or prevention of infections in particular bacterial diseases, virus diseases and/or mycoses.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns a tannin derivative, in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin, the covalent coupling is formed as an ester or ether bond, and wherein the acid residue provides at least one functional group for covalently coupling at least one pharmaceutically active ingredient, a pharmaceutical composition comprising or consisting of said tannin derivative and a method for producing said tannin derivatives.

Description

Specification
Tannin derivative and pharmaceutical compositions comprising said tannin derivative
The present invention relates to a tannin derivative, in particular tannin derivative having antibiotic activity and pharmaceutical compositions comprising said tannin derivative.
Tannins are distributed in species throughout the plant kingdom. They are commonly found in both gymnosperms as well as angiosperms. A tannin (also known as vegetable tannin, natural organic tannins or sometimes tannoid, i.e. a type of biomolecule, as opposed to modern synthetic tannin) is an astringent, bitter plant polyphenolic compound that binds to and precipitates proteins and various other organic compounds including amino acids and alkaloids. The term tannin in the context of the present invention comprises any large polyphenolic compound containing sufficient hydroxyls and other suitable groups (such as carboxyls) to form strong complexes with proteins and other macromolecules.
The tannin compounds play a key role in protection of plants from predation by fungi, insects and other abiotic agents. Tannin compounds are also supposed to play a key role as pesticides, and in plant growth regulation. The astringency of tannins is what causes the dry and puckery feeling in the mouth following the consumption of unripened fruit or red wine. Likewise, the destruction or modification of tannins with time plays an important role in the ripening of fruit and the aging of wine.
Tannins have molecular weights ranging from 500 to over 3,000 (gallic acid esters) and up to 20,000 (proanthocyanidins). Tannins are incompatible with alkalis, gelatin, heavy metals, iron, limewater, metallic salts, strong oxidizing agents and zinc sulfate, since they form complexes and precipitate in aqueous solution.
It is known in the art that when incubated with substances having a high content of condensed tannins, the poliovirus, herpes simplex virus, and various enteric viruses are inactivated. Tannins have thus shown potential antiviral, antibacterial and antiparasitic effects. It was also confirmed that tannins isolated from the stem bark also have antiinflammatory and antiulcer activity in rodents, showing a strong antioxidant property with possible therapeutic applications.
Tannin derivative galloyi glucose is a chemical compound formed from gallic acid and β- D-glucose. It can be found in oaks species like the North American white oak (Quercus alba) and European red oak (Quercus robur) and may be synthesized artificially. Galloyi glucose is formed by a gallate 1 -beta-glucosyltransferase (UDP-glucose: gallate glucosyl transferase), an enzyme performing the esterification of two substrates, UDP- glucose and gallate to yield two products, UDP and 1 -galloyl-beta-D-glucose (glucogallin). This enzyme can be found i.a. in oak leaves preparations.
Galloyi glucose carbon acid esters are substances having various properties that are about to exhibit pharmacological interest. Synthesis currently used provide for a derivatisation of gallic acid and coupling said gallic acid with glucose to yield galloyi glucose directly employable as antibiotic agent. The present invention however provides for the derivatisation of the entire molecule of galloyi glucose wherein the hydroxy groups of galloyi glucose become chemically modified.
US 2002/151582 (Tea polyphenol esters and analogs thereof for cancer prevention and treatment) dicloses an ester of pentagalloyl-monogallic acid. Molecukes presented in this document are Epigallocatechines with no glucose molecule incorporated in the basic structure
US2008/0319185 discloses pentagalloyl glucose having hydroxy groups of gallic acid derivatized with benzen groups for mere stabilisation purposes.
Enzymatic esterification is the first step in the biosynthesis of galloyi glucose or gallotannins. The molecule is then used by enzymes in the gallotannins synthetis pathway like beta-glucogallin O-galloyl transferase or beta-glucogallin-tetra-cis-galloyl glucose O-galloyl transferase.
Prior art anti-infective drug substances such as classical antibiotics have the disadvantage of decreasing efficiency due to increasing host resistance. Further these substances are found only effective against bacterial infections. Due to increasing occurrence of e.g. bacterial and fungal co-infections there is an increasing need of drug substances with increased efficiency against multiple microbial agents.
The present invention provides for tannin derivatives and a pharmaceutical compositions comprising said tannin derivative, effective for the treatment of multiple infections by different microbial agents. Furthermore, the tannin of the inventions provides for a vehicle to co-administer antimicrobial and other drug substances to a subject in need thereof. The invention thus provides for a molecule that may be applied in the synthesis of various drug substances useful for the synthesis of pharmaceutical compositions useful for treating co-infective diseases.
The invention provides for tannin derivative, in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin. The main aspect of the present invention is, that the covalent coupling is formed as an ester or ether bond. The acid residue thus provides at least one functional group for covalently coupling at least one pharmaceutically active ingredient.
In one embodiment of the present invention there is provided a tannin derivative in which the at least one organic acid provides one or more aromatic groups.
In yet another embodiment of the present invention there is provided a tannin derivative wherein the at least one tannin provides one or more substitutable hydroxyl groups.
In a further embodiment of the present invention the at least one tannin is selected from the group consisting of 1 -galloyl glucose, 2-galloyl glucose, tri-galloyl glucose, 4-galloyl glucose, penta-galloyl glucose or mixtures thereof.
In a preferred embodiment of the present invention the aromatic acid is selected from the group consisting of aromatic carboxylic acids such as amines, halogens and/or hydroxyl-containing aromatic carboxylic acids, benzoic acid or derivatives and/or mixtures thereof.
Preferably the tannin derivative provides a coupling of two or more identical or different aromatic acids, in particular wherein the aromatic acid is a pharmaceutically acceptable acid. In a further embodiment of the invention the at least one pharmaceutically active ingredient covalently coupled to the at least one functional group is selected from the group consisting of antibiotics, antifungals, cytostatics, antivirals, fungistatics, analgesics or combinations thereof.
It is particularly preferred if the at least one pharmaceutically active ingredient is selected from the group consisting of HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV- effective antivirals or combinations thereof. The tannin derivative of the invention thus provided antibiotic properties via the basic tannin structure or compound whereas this properties are completed by an antiviral property. The preferred embodiment ma ythus be empoyed in the treatment of multiple infections with various pathogens in general requiring different active agents. The invention composition thus enables treatment of different pathogens with a single multiactive compound.
In a further embodiment of the invention in the tannin derivative the at least one pharmaceutically active ingredient is selected from the group consisting of β-lactame antibiotics, gram-positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics or combinations thereof. The pharmaceutically active ingredient thus increases the efficiency of the underlying tannin derivative and provides for a broader range of antibiotic activity of the compound. Treatment of bacteria with increased resistance can thus be achieved with a single coumpound by different ways of pharmaceutical activity.
In a further embodiment the at least one pharmaceutically active ingredient is selected from the group consisting of polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines echinocandins or combinatons thereof. The tannin derivative thus combines antibiotic with antifungal activity. The invention tannin derivative thus provide for a pharmaceutical compositions useful for treating co-infective diseases.
In a particularly preferred embodiment the at least one pharmaceutically active ingredient is selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p-aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid,
phenoxyacetic acid, phenylacrylic acid, serine, styrylacetic acid, (S)-2-{4-[(2-4- diaminopteridin-6-yl methyl) methylamino] benzoylamino} pentandi acid, threonine, tryptophane, tyrosine, valine, sorbic acid, 1 ,2,4-triazol-3-carboxylic acid, 3-(thienyl)- malonic acid, 4-morpholine carboxylic acid, amethopterine (methotrexate), 9-(2- carboxyethoxymethyl)-guanin, 4-thiazolidincarbon acid, imidazolacrylic acid, or derivatives and/or combinations thereof.
Preferably the tannin derivative, in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin provides for the covalent coupling being formed as an ester or ether bond. In a particular embodiment contemplated by the present invention the acid residue provides at least one functional group for covalently coupling two or more pharmaceutically active ingredients. The pharmaceutically active ingredients are preferably functionally and/or structurally identical or similar or functionally and/or structurally different. The invention tannin derivative provides for integration of pharmaceutically active ingredients within molecule, whereas the pharmaceutically active ingredients and thus the molecule are adapted to treatment of various infections or infective indications occuring in an individual simultaneously or consecutively. Preferably said two or more
pharmaceutically active ingredients, in particular functionally and/or structurally identical or functionally and/or structurally different pharmaceutically active ingredients are selected from the group consisting of antibiotics, preferably β-lactame antibiotics, gram- positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics, antifungals, preferably polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines or echinocandins, cytostatics, antivirals, preferably HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV-effective antivirals and fungistatics, analgesics. It is a particular advantage of the present invention that combinations of the aforesaid active ingredients may be combined in a single molecule. The effect of co-administration may thus be achieved by a single adaptive molecule combining several in particular complementary pharmaceutically active ingredients.
In an embodiment of the latter tannin derivative the two or more pharmaceutically active ingredients, in particular functionally and/or structurally identical or similar or functionally and/or structurally different pharmaceutically active ingredients are selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p-aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid, phenoxyacetic acid, phenylacrylic acid, serine, styrylacetic acid, (S)-2-{4-[(2-4-diaminopteridin-6-yl methyl) methylamino]
benzoylamino} pentandi acid, threonine, tryptophane, tyrosine, valine, sorbic acid, 1 ,2,4- triazol-3-carboxylic acid, 3-(thienyl)-malonic acid, 4-morpholine carboxylic acid, amethopterine (methotrexate), 9-(2-carboxyethoxymethyl)-guanin, 4-thiazolidincarbon acid, imidazolacrylic acid, or derivatives and/or combinations thereof.
In one embodiment of the tannin derivative according to the invention the tannin derivative is selected from a composition of formula (A),
Figure imgf000007_0001
wherein R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same, similar or different pharmaceutically active ingredients.
In a further embodiment, the tannin derivative is selected from a composition of formula (B),
Figure imgf000008_0001
wherein R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same, similar or different pharmaceutically active ingredients.
In a further embodiment the tannin derivative is selected from a composition of formula (C),
Figure imgf000008_0002
wherein R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same, similar or different pharmaceutically active ingredients.
In all of the aformentioned embodiments the tannin derivative provides for a multitude of binding sites for pharmaceutically active ingredients. Thus a macromolecule may be synthesised comprising on or more pharmaceutically active ingredients. The antibiotic activity of the underlying tannin may thus be combined with further pharmaceutical activity and allow for co-administration of pharmaceutically active ingredients thus increasing efficiency of treatment and reducing potential negative side effects.
Formula A shows galloyi glucose derivatised with p-aminobenzic acid, p-aminobenzic acid can be replaced by other pharmaceutically active molecules such as other carbon acids. Coupling is effected by an ester group as shown in formula A. However ester group may be substituted by an ether group or any other chemical binding agent as shown e.g. in formula B. An extension of the pharmaceutically active band width can be achieved by chemically binding further pharmaceutically active molecules (e.g. as defined above) to galloyi glucose. In particular long chained carbon acids could improve membrane permeability of the molecule. Additionally coupling with e.g. vitamine molecules can be useful for infiltration of bacterial cells. A particularly preferred active variant is the additional or sole coupling of beta-lactame molecule. Formula C suggests how a terminal amino group of derivated galloyi glucose as shown in formula A can be coupled using Hantzsch reaction with a further pharmaceutically active group of molecules.
As the basic molecule of galloyi glucose is able to form complexes of iron ions and to unspecifically denature proteins, the derivatisation of galloyi glucose as described above further provides additional modes of action against pathogens.
As in for example pentagalloyl glucose there are 15 hydroxy groups ready for derivatisation, a wide range of variation exists. Pharmaceutically active ingredients are used to merely influence only a single enzymatically important mechanism. The derivatisation as described above provides the possibility of influencing or even block multiple or different biochemical activities using a single molecule. The invention particularly aims at pathogens that tend to form multiple resistances and provides several modes of action by selcting suitable pharmaceutically active ingredients such as a combination of antivirals and antibiotics or antibiotics and antifungals or antifungals, antibiotics and antivirals. This could be used in the treatment of multiple simultaneous or sequential infections with different or various pathogen (fungi, virus, bacteria etc.) related to diseases such as for example HIV infections.
The present invention also provides for a pharmaceutical composition comprising or consisting of at least one tannin derivative as defined above. In a preferred embodiment of the present invention said pharmaceutical composition has a solid, orally administrable form, a liquid, orally administrable form, an injectably administrable form or in form of an ointment, an emulsion or a suspension.
The dosage form comprises a mixture of pharmaceutical composition and excipients and may be pressed or compacted from a powder into a solid dose or mixed to form a liquid orally administrable form, an injectably administrable form or an ointment, an emulsion or a suspension. The excipients can include but are not limited to diluents, binders or granulating agents, flow aids and lubricants to ensure efficient tabletting; disintegrants to promote tablet break-up in the digestive tract; sweeteners or flavours to enhance taste; and pigments to make the tablets or other adminstrable forms visually attractive. The pharmaceutical composition may be provided in a form administrable orally, sublingually, buccally, rectally or intravaginally. Further contemplated administrable forms are syrups, elixirs, suspensions, and emulsions.
Derivatives, in particular of galloyi glucose and aromatic carbon acids as well as combinations of galloyi glucose and derivatives of the latter, preferably comprising amino, halogen or hydroxyl groups exhibit strong antimicrobial properties.
To ensure membrane permeability derivatives of the molecule preferably have a terminal carbon chain of suitable length.
The galloyi glucose derivative metabolized in a pathogen, i.e. a bacterial cell, denatures proteins which, in the case of bacteria may avoid formation of resistance.
Furthermore, galloyi glucose derivative is able to form a complex with iron ions. This process will result in a reduction of iron availability within the microbial cell.
Tannin derivatives of the present invention thus provide antibacterial, antifungal, antiviral activity. Due to free hydroxyl groups anticancerogen activity is encompassed as well.
The present invention contemplates a method for producing a tannin derivatives, comprising the steps of i) providing a tannin, and ii) covalently coupling at least one aromatic acid or an acid derivative with at least one hydroxyl group of the tannin and iii) covalently coupling at least one pharmaceutically active ingredient as specified above with at least one functional group defined by the aromatic acid residue of the tannin derivative as specified above. In an embodiment of the invention method ii) covalently coupling at least one aromatic acid or an acid derivative with at least one hydroxyl group of the tannin provides for an esterification or etherification of the aromatic acid or acid derivative in the presence of an alcohol and/or an acid.
In yet another embodiment of the invention method a selective coupling with individual hydroxyl groups is provided. In particular such selection is performed by binding of suitable protecting groups with the hydroxyl groups. By removing selected protecting groups in the process of manufacture coupling may be directed to predetermined hydroxyl groups to further specify binding ability and selectivity of the invention pharmaceutical compositions. Protection groups suitable for use with the invention method are readily available for the skilled person.
In a preferred embodiment of the invention method coupling is effected in a Hantzsch reaction. Even though Hantzsch reaction is the preferred reaction for effecting coupling of the tannin derivative with pharmaceutically active ingredients, the invention also contemplated the use of other reactions, such as e.g. Biginelli reactions, mannich reactions and passerine reactions, without restricting the invention to the aforementioned reactions. Persons skilled in the art are completely aware of possible modifications and further reactions that may be employed in the context of the invention method and are covered. These modifications are contemplated by the invention.
The invention also provides for a pharmaceutical or pharmaceutical composition comprising or consisting of the invention tannin derivative as specified above for use in medicine.
In one embodiment of the invention the pharmaceutical or pharmaceutical composition comprising or consisting of the invention tannin derivative as specified above is used as an antibiotic, antifungal, cytostatic, antiviral, analgesic and/or fungistatic or a combination of the aforesaid.
The invention pharmaceutical or pharmaceutical composition comprising or consisting of a tannin derivative as specified above is preferably employed for the therapy or prevention of infections, in particular bacterial diseases, virus diseases and/or mycoses.
The invention contemplates synthesis between galloyl glucose and substituted aromatic acids. The isolated reaction product was tested with a test from milk industry, wherein Lactobacillus reduces the dyes methylene blue and brilliant black to a colorless form. If the reaction product is present in the medium no growth of Lactobacillus is reported. The dyes stay blue or black thus proving the reaction product of galloyl glucose and substituted aromatic acids to be effective as antimicrobial agent.
Furthermore, the invention contemplates that each hydroxyl group in the molecule of various tannins, in particular galloyl glucose, can be used to make another substitution. Reaction may be directed by the use of specific protection groups. The invention encompasses the case that the linking molecule, e. g. a pharmaceutically and physiologically acceptable substituted aromatic acids provides for a residual amino group, this amino group is used for a reaction, in particular Hantzsch reaction or any other suitable reaction, to build a pyrimidine, e.g. di-hydro-di-acetyl-pyrimidine which may be used as a precursor for a functionalized molecule.
EXAMPLES
Example 1
Experimental Synthesis of molecule galloyl glucose-para-amino-benzoic acid ester Synthesis
1 ,7g tannin and 5,1 g p-amino benzoic acid are placed with 50g Ν,Ν-dimethyl formamid in a 250ml 3-neck vessel. On top of the vessel was placed a water separation funnel with a cooler. Warming yielded a clear, brown solution. A solution consisting of 1 ,3g p- toluene sulfonic acid in 13g Ν,Ν-Dimethyl formamid and 86, 5g dry toluene was added. After 60 minutes of boiling 0,46g water was separated in the graduated water measuring funnel. The heating was stopped. To avoid oxidization of tannin synthesis steps were performed inert gas atmospheric conditions.
Isolation
The reaction mixture was mixed with the same weight of n-hexane in a separating funnel. Following phase separation a heavy phase in the form of dark oil remained. The remaining n-hexane was removed by incubation in a 40°C bain-marie. Transition from free base into hydrochloride was performed using 1 -n hydrochloride acid under pH control. The weak acidic solution was mixed with 1 g of charcoal, filtered and incubated at 36°C in a crystallization glass for 24hrs. The resulting product was filtered and dried in a vacuum desiccator overnight. The synthesis yielded 1 ,49g of a brownish substance exhibiting perpendicularly, chromatic crystals in polarized light
Microbial growing test of Lactobacillus confirmed the antimicrobial activity of the yielded substance even if present in the growth medium at very low concentrations.
Example 2
Synthesis of Tri-galloyl-glucose-di-hydro-di-acetyl-pyrimidin
Tri-galloyl glucose (Corilagin) having the chemical formula C27H24O18 and a molecular weight of 636,47 is covalently coupled with physiologically acceptable p-Amino-benzoic acid by an ester bond thereby yielding p-Amino-benzoic acid-ester. In a subsequent Hantzsch reaction a pharmaceutically active ingredient Di-methyl-di-acetyl-pyrimidin- benzaldehyd is coupled to a functional group of p-Amino-benzoic acid-ester thus providing a functionalized molecule having on the one hand antibiotic characteristics provided by the tannin derivative on the other hand antianginal and antihypersensitive characteristics provided by the pharmaceutically active ingredient. As an alternative penta-galloyl glucose can be used, without restricting the invention to the aforesaid compounds.
Example 2
In 50g waterfree Ν,Ν-Dimethylformamide (DMF) 1 ,7g Tannine (Riedel de Haen Art. Nr. 16201 Lot. Nr. 30500) and 5,1 g p-aminobenzoic acid are resolved by heating. A solution consisting of 1 ,3g p-toluolsulon acid in 13g DMF are added. Further 86, 5g toluol are added as water binding agent. After 60 minutes of Reflux cooking at approx. 1 18°C 0,45g water are precipitated and reaction is terminated. Preparation of the reaction mixture (RGM) is effected by adding 30ml 1 -n HCI and repeated agitation in the presence of Ligroin for complete removal of toluol until ligroine phase weight shows no further increase. The heavy phase containing the product as hydrochloride is stirred in the presence of 1 g active carbon, filtered. The filtrate is set aside for cristallisation at +36°C. After approx. 24 hrs the cristals are aspired, dried and weighed.
Weight: 1 ,49g. In linear polarised light of the microscope coloured square-shaped cristals are detected. In HPLC the product could be verified as being free of educts. In example 2 experimentation was done under CO2-atmosphere.
Example 3
In 20g Ν,Ν-Dimethylformamid (DMF) 1 ,08g tannine (Riedel de Haen Art.Nr. 16201 Lot.Nr. 30500) and 1 ,2g p-aminobenzoic acid are resolved at 30°C. At T of 60°C 600μΙ_ H2SO4 cone, were added and allowed top react at 95°C. After 130 min. of reaction product formation is widly terminated. Higher temperature and higher amounts of H2SO4 can shorten reaction time required. This could be verified in example 4 (cf. below).
Example 4
In 50g Ν,Ν-Dimethylformamid (DMF) 6,0g tannine (Riedel de Haen Art.Nr. 16201 Lot.Nr. 30500) and 6,0g p-aminobenzic acid are resolved at 30°C. At T of 60°C 3ml H2SO4 cone, are added allowed to react at T=103°C. bain-marie was set to 107°C. After 85 min. of reaction product formation is terminated. Higher temperature and higher amounts of H2SO4 may shorten reaction time required.
Sample dilution for HPLC: 1 :2000 with mobile phase.
Chromatographic Conditions for HPLC:
Column: ODS 5μ 150x6,35x4,0 (LxODxID in mm), mobile phase A consists of 985g Wasser, 6,66g KH2PO4 and 9,3g H3PO4 . pH is 2,5. Mobile phase B is CH3CN. A:B= 80:20 (v/v). Flux rate 1 ml/min. Detection 254nm. INJVOL=10 L. column pressure at RT approx. 100bar (+/- approx. 50bar). p-aminobenzic acid eluates at approx. 2,12 min, the product at approx. 2,45 min. Tannine eluates in close proximity to dead time. Dilution of sample for examples 2 and 3 is 1 :1000 with mobile phase. With different weight preparations dilution is adapted, accordingly. As internal test substances aromatic carbon acids may be used, such as e.g. benzoic acid.
The invention comprises the following items:
A tannin derivative, in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin wherein the covalent coupling is formed as an ester or ether bond, and wherein the acid residue provides at least one functional group for covalently coupling at least one pharmaceutically active ingredient.
A tannin derivative wherein the at least one organic acid provides one or more aromatic groups.
A tannin derivative wherein the at least one tannin provides one or more substitutable hydroxyl groups.
A tannin derivative wherein the at least one tannin is selected from the group consisting of 1 -galloyl glucose, 2- galloyl glucose, tri-galloyl glucose, 4- galloyl glucose, penta- galloyl glucose or mixtures thereof.
A tannin derivative wherein the aromatic acid is selected from the group consisting of aromatic carboxylic acids such as amines, halogens and/or hydroxyl-containing aromatic carboxylic acids, benzoic acid or derivatives and/or mixtures thereof.
A tannin derivative wherein coupling of two or more identical or different aromatic acids is provided, preferably wherein the aromatic acid is a pharmaceutically acceptable acid.
A tannin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of antibiotics, antifungals, cytostatics, antivirals, fungistatics, analgesics or combinations thereof.
A tannin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV- effective antivirals or combinations thereof.
A tannin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of β-lactame antibiotics, gram-positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics or combinations thereof.
A tannin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines echinocandins or combinatons thereof.
At annin derivative wherein the at least one pharmaceutically active ingredient is selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p- aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid, phenoxyacetic acid, phenylacrylic acid, serine, styrylacetic acid, (S)-2-{4-[(2-4-diaminopteridin-6-yl methyl) methylamino] benzoylamino} pentandi acid, threonine, tryptophane, tyrosine, valine, sorbic acid, 1 ,2,4-triazol-3-carboxylic acid, 3-(thienyl)-malonic acid, 4-morpholine carboxylic acid, amethopterine (methotrexate), 9-(2-carboxyethoxymethyl)-guanin, 4- thiazolidincarbon acid, imidazolacrylic acid, or derivatives and/or combinations thereof.
A tannin derivative, in particular tannin derivative having antibiotic activity, obtained by covalent coupling of at least one organic acid with at least one tannin wherein the covalent coupling is formed as an ester or ether bond, and wherein the acid residue provides at least one functional group for covalently coupling two or more
pharmaceutically active ingredients, in particular functionally identical or functionally different pharmaceutically active ingredients.
A tannin derivative wherein said two or more pharmaceutically active ingredients, in particular functionally identical or functionally different pharmaceutically active ingredients are selected from the group consisting of antibiotics, preferably β-lactame antibiotics, gram-positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics, antifungals, preferably polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines or echinocandins, cytostatics, antivirals, preferably HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV-effective antivirals and fungistatics, analgesics or combinations thereof.
A tannin derivative wherein said two or more pharmaceutically active ingredients, in particular functionally identical or functionally different pharmaceutically active ingredients are selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p-aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid,
phenoxyacetic acid, phenylacrylic acid, serine, styrylacetic acid, (S)-2-{4-[(2-4- diaminopteridin-6-yl methyl) methylamino] benzoylamino} pentandi acid, threonine, tryptophane, tyrosine, valine, sorbic acid, 1 ,2,4-triazol-3-carboxylic acid, 3-(thienyl)- malonic acid, 4-morpholine carboxylic acid, amethopterine (methotrexate), 9-(2- carboxyethoxymethyl)-guanin, 4-thiazolidincarbon acid, imidazolacrylic acid, or derivatives and/or combinations thereof.
A tannin derivative wherein the tannin derivative is selected from a composition of formula (A),
Figure imgf000017_0001
wherein R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same or different pharmaceutically active ingredients.
A tannin derivative wherein the tannin derivative is selected from a composition of formula (B),
Figure imgf000017_0002
wherein R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same or different pharmaceutically active ingredients
A tannin derivative, wherein the tannin derivative is selected from a composition of formula (C),
Figure imgf000018_0001
wherein R independently represents at least one covalently coupled pharmaceutically active ingredient as defined above, in particular wherein R represents the same or different pharmaceutically active ingredients.
A pharmaceutical composition comprising a tannin derivative as defined before in particular in a solid, orally administrable form, a liquid, orally administrable form, an injectably administrable form or in form of an ointment, an emulsion or a suspension.
A Method for producing a tannin derivatives as specified above, comprising the steps of: i) providing a tannin, and ii) covalently coupling at least one aromatic acid or an acid derivative with at least one hydroxyl group of the tannin and iii) covalently coupling at least one pharmaceutically active ingredient with at least one functional group defined by the aromatic acid residue of the tannin derivative as specified above . The aforementionned method wherein step ii) provides an esterification or etherification of the aromatic acid or acid derivative in the presence of an alcohol and/or an acid.
The aforementionned method wherein selective coupling with individual hydroxyl groups is provided, in particular wherein the selection is performed by binding of suitable protecting groups with the hydroxyl groups.
The aforementionned method wherein the coupling is effected in a Hantzsch reaction.
A pharmaceutical comprising or consisting of a tannin derivative as specified above or a pharmaceutical composition as defined above for use in medicine.
A pharmaceutical for use as an antibiotic, antifungal, cytostatic, antiviral and/or fungistatic.
A pharmaceutical for the therapy or prevention of infections, in particular bacterial diseases, virus diseases and/or mycoses.

Claims

1 . Tannin derivative, in particular tannin derivative having antibiotic activity,
obtained by covalent coupling of at least one organic acid with at least one tannin characterized in that the covalent coupling is formed as an ester or ether bond, and wherein the acid residue provides at least one functional group for covalently coupling at least one pharmaceutically active ingredient.
2. Tannin derivative according to claim 1 , characterized in that the at least one organic acid provides one or more aromatic groups.
3. Tannin derivative according to claim 1 or 2, characterized in that the at least one tannin provides one or more substitutable hydroxyl groups.
4. Tannin derivative according to any one of the preceding claims, characterized in that the at least one tannin is selected from the group consisting of 1 -galloyl glucose, 2- galloyl glucose, tri-galloyl glucose, 4- galloyl glucose, penta-galloyl glucose or mixtures thereof.
5. Tannin derivative, characterized in that the aromatic acid is selected from the group consisting of aromatic carboxylic acids such as amines, halogens and/or hydroxyl-containing aromatic carboxylic acids, benzoic acid or derivatives and/or mixtures thereof.
6. Tannin derivative, characterized in that coupling of two or more identical or different aromatic acids is provided, preferably wherein the aromatic acid is a pharmaceutically acceptable acid.
7. Tannin derivative according to any of claims 1 to 6, characterized in that the at least one pharmaceutically active ingredient is selected from the group consisting of antibiotics, antifungals, cytostatics, antivirals, fungistatics, analgesics or combinations thereof.
8. Tannin derivative according to any of claims 1 to 7, characterized in that the at least one pharmaceutically active ingredient is selected from the group consisting of HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV-effective antivirals or
combinations thereof.
9. Tannin derivative according to any of claims 1 to 7, characterized in that the at least one pharmaceutically active ingredient is selected from the group consisting of β-lactame antibiotics, gram-positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics or combinations thereof.
10. Tannin derivative according to any of claims 1 to 7, characterized in that the at least one pharmaceutically active ingredient is selected from the group consisting of polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines echinocandins or combinatons thereof.
1 1 .Tannin derivative according to any of claims 1 to 7, characterized in that the at least one pharmaceutically active ingredient is selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p-aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid, phenoxyacetic acid, phenylacrylic acid, serine, styrylacetic acid, (S)-2-{4-[(2-4-diaminopteridin-6-yl methyl) methylamino] benzoyl ami no} pentandi acid, threonine, tryptophane, tyrosine, valine, sorbic acid, 1 ,2,4-triazol-3-carboxylic acid, 3-(thienyl)-malonic acid, 4- morpholine carboxylic acid, amethopterine (methotrexate), 9-(2- carboxyethoxymethyl)-guanin, 4-thiazolidincarbon acid, imidazolacrylic acid, or derivatives and/or combinations thereof.
12. Tannin derivative, in particular tannin derivative having antibiotic activity,
obtained by covalent coupling of at least one organic acid with at least one tannin characterized in that the covalent coupling is formed as an ester or ether bond, and wherein the acid residue provides at least one functional group for covalently coupling two or more pharmaceutically active ingredients, in particular
functionally identical or functionally different pharmaceutically active ingredients.
13. Tannin derivative, according to claim 12, characterized in that said two or more pharmaceutically active ingredients, in particular functionally identical or functionally different pharmaceutically active ingredients are selected from the group consisting of antibiotics, preferably β-lactame antibiotics, gram-positive effective antibiotics, gram negative effective antivbiotics, polypeptide antibiotics, chinolone antibiotics, polyketide antibiotics, sulfionamiude antibiotics, amino glucoside antibiotics, antifungals, preferably polyene antifungals, midazole, triazole, and thiazole antifungals, allylamines or echinocandins, cytostatics, antivirals, preferably HIV-, HCV-, HBV, HSV, HRSV, HRV and VZV-effective antivirals and fungistatics, analgesics or combinations thereof.
14. Tannin derivative according to any of claims 12, characterized in that said two or more pharmaceutically active ingredients, in particular functionally identical or functionally different pharmaceutically active ingredients are selected from the group consisting of 7-aminocephalosporanic acid, acetylsalicylic acid, alanine, benzoic acid, benzylpenicillic acid, benzylpenicilloic acid, biotine, caprylic acid, cinnamic acid, cystein, dihydrofolic acid, folic acid, folinic acid, glutaminic acid, glycine, histidine, hydroxybenzoic acid, leucine, linoleic acid, lysine, nicotinic acid, p-aminobenzoic acid, p-aminosalicylic acid, phenylacetic acid,
phenoxyacetic acid, phenylacrylic acid, serine, styrylacetic acid, (S)-2-{4-[(2-4- diaminopteridin-6-yl methyl) methylamino] benzoylamino} pentandi acid, threonine, tryptophane, tyrosine, valine, sorbic acid, 1 ,2,4-triazol-3-carboxylic acid, 3-(thienyl)-malonic acid, 4-morpholine carboxylic acid, amethopterine (methotrexate), 9-(2-carboxyethoxymethyl)-guanin, 4-thiazolidincarbon acid, imidazolacrylic acid, or derivatives and/or combinations thereof.
15. Tannin derivative according to claim any of the preceeding claims wherein the tannin derivative is selected from a composition of formula (A),
Figure imgf000023_0001
wherein R independently represents at least one covalently coupled pharmaceutically active ingredient as defined in any of claims 7 to 10, in particular wherein R represents the same or different pharmaceutically active ingredients.
16. Tannin derivative according to claim any of claims 1 to 14, wherein the tannin derivative is selected from a composition of formula (B),
Figure imgf000023_0002
wherein R independently represents at least one covalently coupled pharmaceutically active ingredient as defined in any of claims 7 to 10, in particular wherein R represents the same or different pharmaceutically active ingredients
17. Tannin derivative according to claim any of claims 1 to 14 wherein the tannin derivative is selected from a composition of formula (C),
Figure imgf000024_0001
wherein R independently represents at least one covalently coupled
pharmaceutically active ingredient as defined in any of claims 7 to 10, in particular wherein R represents the same or different pharmaceutically active ingredients.
18. Pharmaceutical composition comprising a tannin derivative as defined in any of the preceding claims in particular in a solid, orally administrable form, a liquid, orally administrable form, an injectably administrable form or in form of an ointment, an emulsion or a suspension.
19. Method for producing a tannin derivatives as specified by claims 1 to 15,
comprising the steps of: i) providing a tannin, and ii) covalently coupling at least one aromatic acid or an acid derivative with at least one hydroxyl group of the tannin and iii) covalently coupling at least one pharmaceutically active ingredient with at least one functional group defined by the aromatic acid residue of the tannin derivative as specified in claim 5 or 6.
20. The method of claim 19, characterized in that step ii) provides an esterification or etherification of the aromatic acid or acid derivative in the presence of an alcohol and/or an acid.
21 .Method according to claim 19 or 20, characterized in that selective coupling with individual hydroxyl groups is provided, in particular wherein the selection is performed by binding of suitable protecting groups with the hydroxyl groups.
22. Method according to any one of claims 19 to 21 , characterized in that the
coupling is effected in a Hantzsch reaction.
23. Pharmaceutical comprising or consisting of a tannin derivative as specified in claims 1 to 15 or a pharmaceutical composition as defined in claim 18 for use in medicine.
24. Pharmaceutical according to claim 23 for use as an antibiotic, antifungal,
cytostatic, antiviral and/or fungistatic.
25. Pharmaceutical according to claim 23 or 24 for the therapy or prevention of infections, in particular bacterial diseases, virus diseases and/or mycoses.
PCT/EP2013/076140 2012-12-11 2013-12-10 Tannin derivative and pharmaceutical compositions comprising said tannin derivative Ceased WO2014090832A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12196610 2012-12-11
EP12196610.5 2012-12-11

Publications (1)

Publication Number Publication Date
WO2014090832A1 true WO2014090832A1 (en) 2014-06-19

Family

ID=47355869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/076140 Ceased WO2014090832A1 (en) 2012-12-11 2013-12-10 Tannin derivative and pharmaceutical compositions comprising said tannin derivative

Country Status (1)

Country Link
WO (1) WO2014090832A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019077954A (en) * 2014-11-11 2019-05-23 国立研究開発法人物質・材料研究機構 Coating forming method of forming film on base material using coating formative composition including tannic acid derivative and film including tannic acid derivative formed on base material
CN112451535A (en) * 2020-06-11 2021-03-09 广东盛普生命科技有限公司 Application of 1,4, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
WO2021211201A1 (en) * 2020-04-15 2021-10-21 Purdue Research Foundation Novel flame retardant resin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078699A1 (en) * 1999-06-18 2000-12-28 E.I. Du Pont De Nemours Oxidative cleavage of unsaturated oils and products obtained therefrom
US20020151582A1 (en) * 2000-10-11 2002-10-17 Dou Q. Ping Tea polyphenol esters and analogs thereof for cancer prevention and treatment
EP1754702A1 (en) * 2004-05-27 2007-02-21 Suntory Limited Epigallocatechin dimers or trimers having lipase inhibitory activity and/or antioxidative activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078699A1 (en) * 1999-06-18 2000-12-28 E.I. Du Pont De Nemours Oxidative cleavage of unsaturated oils and products obtained therefrom
US20020151582A1 (en) * 2000-10-11 2002-10-17 Dou Q. Ping Tea polyphenol esters and analogs thereof for cancer prevention and treatment
EP1754702A1 (en) * 2004-05-27 2007-02-21 Suntory Limited Epigallocatechin dimers or trimers having lipase inhibitory activity and/or antioxidative activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIANHAI LI AND TAK HANG CHAN: "Enantioselective Synthesis of Epigallocatechin-3-gallate (EGCG), the Active Polyphenol Component from Green Tea", ORGANIC LETTERS, vol. 3, no. 5, 13 February 2001 (2001-02-13), web, pages 739 - 741, XP002697021 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019077954A (en) * 2014-11-11 2019-05-23 国立研究開発法人物質・材料研究機構 Coating forming method of forming film on base material using coating formative composition including tannic acid derivative and film including tannic acid derivative formed on base material
WO2021211201A1 (en) * 2020-04-15 2021-10-21 Purdue Research Foundation Novel flame retardant resin
CN112451535A (en) * 2020-06-11 2021-03-09 广东盛普生命科技有限公司 Application of 1,4, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine

Similar Documents

Publication Publication Date Title
CN104114176A (en) Maillard reaction inhibitor
WO2008099994A1 (en) Biphenyl diol derivatives and compositions comprising the same as an active ingredient
JPWO2006090830A1 (en) Proanthocyanidin oligomer production method
MX2014015249A (en) N-substituted second generation derivatives of antifungal antibiotic amphotericin b and methods of their preparation and application.
DK2509984T3 (en) FUNGICIDE COMPOSITIONS AND PROCEDURES FOR USE THEREOF
KR101376231B1 (en) Composition for inhibiting the activity of neuraminidase and pharmaceutical composition for prevention and treatment of influenza viral diseases comprising extracts of young barley leaves
WO2014090832A1 (en) Tannin derivative and pharmaceutical compositions comprising said tannin derivative
JP5717317B2 (en) Pharmaceutical use of compounds
Divya et al. GC-MS analysis, antimicrobial, antioxidant activity of an Ayurvedic medicine, Salmali Niryasa
JP2005298379A (en) IkappaB KINASE INHIBITOR
KR20220021684A (en) Composition for preventing or treating gastric cancer comprising narcenicin A1 derivative
WO2017216813A1 (en) Composition to reduce dna and hepatic damage and to enhance repair thereof
Hwang et al. Antimicrobial activity of Caesalpinia sappan L. extract against skin flora
US20170349548A1 (en) P21-activated kinase inhibitor
CN102988525A (en) Preparation method for total lignans in hawthorn seeds, and novel application
CN107382930B (en) Compound S-6- [hydroxyl (phenyl) methyl] -2H- pyran-2-one and its preparation and application
RU2435599C1 (en) PREPARATION-4-Hydroxy-17R-Methylincisterol AFFECTING TISSUE EXCHANGE AND APPLICATION OF Pleurotus 1137 FUNGUS STRAIN FOR MAKING IT
US7750114B2 (en) Peptides having a high cysteine content
Rogoza et al. Plant alkaloids of the polymethyleneamine series
CN102911182B (en) Bromophenol compound and application thereof
KR100965304B1 (en) Composition for preventing or treating a disease mediated by overexpression of HSP 27
TW201018462A (en) Novel mixture and compounds from mycelia of antrodia camphorata having hepatoprotection, anti-inflammatory and anti-tumor activities
RU2182174C2 (en) Method of isolation of avermectin complexes
TWI702047B (en) Use of mango extracts and bioactive ingredients obtained therefrom for reducing fat accumulation and oxidative damage in liver
CN103374057B (en) A kind of compound glycine transporter to inhibit activities

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13818989

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13818989

Country of ref document: EP

Kind code of ref document: A1